NeuroPace (NPCE) Return on Capital Employed (2021 - 2026)
NeuroPace's (NPCE) quarterly Return on Capital Employed came in at 19.47% in Q1 2026, up 250.0% year-on-year from 5.56% in Q1 2025, and down 5.6% quarter-over-quarter from 18.44% in Q4 2025.
NeuroPace (NPCE) Return on Capital Employed (2021 - 2026) Analysis & Trends
NeuroPace's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 19.47% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 250.0% year-over-year to 19.47% in Q1 2026; TTM through Mar 2026 was 19.47%, a 250.0% increase from a year earlier, with the FY2025 full-year figure at 19.85%, up 535.0% from the prior year.
- Return on Capital Employed declined to 19.47% in Q1 2026 per NPCE's latest filing, from 18.44% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.44% in Q4 2025 and bottomed at 39.23% in Q1 2023.
- The 5-year median for Return on Capital Employed is 29.29% (2024), against an average of 29.08%.
- Across the five-year window, Return on Capital Employed tumbled 2322 bps in 2022 and surged 994 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 38.37% in 2022, then gained by 19 bps to 31.15% in 2023, then grew by 13 bps to 26.98% in 2024, then soared by 32 bps to 18.44% in 2025, then declined by 6 bps to 19.47% in 2026.
- Per Business Quant, the three latest NPCE Return on Capital Employed figures stand at 19.47% (Q1 2026), 18.44% (Q4 2025), and 20.93% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | -19.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.47% |
| Dec 31, 2025 | -18.44% |
| Sep 30, 2025 | -20.93% |
| Jun 30, 2025 | -21.83% |
| Mar 31, 2025 | -21.97% |
| Dec 31, 2024 | -26.98% |
| Sep 30, 2024 | -28.63% |
| Jun 30, 2024 | -29.48% |
| Mar 31, 2024 | -29.29% |
| Dec 31, 2023 | -31.15% |
| Sep 30, 2023 | -36.36% |
| Jun 30, 2023 | -39.07% |
| Mar 31, 2023 | -39.23% |
| Dec 31, 2022 | -38.37% |
| Sep 30, 2022 | -36.29% |
| Jun 30, 2022 | -32.03% |
| Mar 31, 2022 | -24.85% |
| Dec 31, 2021 | -18.53% |
| Sep 30, 2021 | -13.07% |
| Jun 30, 2021 | -13.87% |